Vimarsana
Biggest News Aggregation in the World

Page 24 - Real World Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Real World Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Real World Data Today - Breaking & Trending Today

Interview: Verana Health's CEO, Sujay Jadhav on diversity and data - Vimarsana News

Interview: Verana Health's CEO, Sujay Jadhav on diversity and data

With the FDA issuing guidance on more diversity within clinical trials, it is a subject many companies are being encouraged to focus on, each with their own approach.

Thermo Fisher Adds Real-World Evidence to Remit Via $912M CorEvitas Acquisition - Vimarsana News

Thermo Fisher Adds Real-World Evidence to Remit Via $912M CorEvitas Acquisition

Corvitas brings Thermo Fisher Scientific registries that gather data about how approved therapies are working in the real world. The acquisition will complement PPD, the contract research organization that Thermo Fisher purchased in 2021.

IQVIA Wins Prestigious "Best AI-based Solution for Healthcare" Award in 2023 Artificial Intelligence Breakthrough Awards | Region - Vimarsana News

IQVIA Wins Prestigious "Best AI-based Solution for Healthcare" Award in 2023 Artificial Intelligence Breakthrough Awards | Region

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jun 27, 2023--

IQVIA Wins Prestigious "Best AI-based Solution for Healthcare" Award in 2023 Artificial Intelligence Breakthrough Awards | Nation/World - Vimarsana News

IQVIA Wins Prestigious "Best AI-based Solution for Healthcare" Award in 2023 Artificial Intelligence Breakthrough Awards | Nation/World

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jun 27, 2023--

Facilitating Review of Real-World Data Studies: The Oncology QCARD - Vimarsana News

Facilitating Review of Real-World Data Studies: The Oncology QCARD

The Oncology QCARD Initiative was designed to facilitate effective communication between study sponsors and protocol reviewers by evaluating the potential minimum elements for sponsors to consider when assembling submissions for review of a proposed study and RWD source(s).

Source: fda.gov